COMMUNIQUÉS West-GlobeNewswire

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
25/04/2024
SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery [...]
Merus annonce les résumés acceptés pour présentation à la réunion annuelle 2024 de l’ASCO
25/04/2024
Pétosemtamab en association avec le pembrolizumab en traitement de première intention du carcinome épidermoïde de la tête et du cou : premières données cliniques provisoires sélectionnées pour une présentation orale [...]
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
24/04/2024
-- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- -- Celebrated Completion of Recent Expansion Program with Grand Opening [...]
Vistin Pharma ASA: Annual Report 2023
24/04/2024
Oslo, Norway, 24 April 2024 Please find attached the Annual Report for 2023 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full year results presented on 16 [...]
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
24/04/2024
PROVIDENCE, Rhode Island, April 24, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. ( NASDAQ : OCEA), today announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that [...]
Amedisys Reports First Quarter 2024 Financial Results
24/04/2024
BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 [...]
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
24/04/2024
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Prolonged survival in Study 102 reinforces pivotal [...]
NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR L’ANNÉE 2023
24/04/2024
L’accord de licence globale de co-développement et de commercialisation avec Janssen Pharmaceutica NV (« Janssen ») étend le potentiel du radioenhancer NBTXR3 à l’échelle internationale. La survie prolongée observée [...]
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]
Hapbee Announces Closing of Private Placement
24/04/2024
Company Raises $2.8 Million From Qualified Investors to Fund Product Development, Market Expansion and Manufacturing VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Hapbee Technologies , Inc. (TSXV: HAPB [...]
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
24/04/2024
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the [...]
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today [...]
STERIS to Host a Conference Call for Fiscal 2024 Fourth Quarter and Full Year Financial Results on May 9, 2024
24/04/2024
DUBLIN, IRELAND, April 24, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 fourth quarter and full year [...]
Entourage Health to Report Fiscal Year 2023 Financial Results
24/04/2024
Company Financials for Full-Year 2023 will be filed after market close on April 29, 2024 TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) ("Entourage" or the " [...]
Spectral AI Schedules 2024 First Quarter Financial Results and Conference Call
24/04/2024
DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
24/04/2024
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
24/04/2024
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR [...]
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
24/04/2024
MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024. The [...]

Pages